SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BarryH who wrote (2091)10/4/1997 12:32:00 PM
From: JOHN W.   of 6136
 
Alex Brown (10/3/97) validates a key point from the conference:

"Adherence" is emerging as one of the most critical determinants of treatment outcome. It is in this context in which our survey of physicians at ICAAC indicates that Agouron's Viracept remains the HIV protease inhibitor of choice, due to its: (1) patient-friendly dosing regimen and (2) excellent side effect profile.."

Question for all the "experts" that are trying to discount Dr. Ho's eradication theory and speculating higher failure rates than the evidence presented by MRK and AGPH. "If your own child was determined to be HIV positive, God forbid, what would you do?"
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News